Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)

被引：3
|
作者：
Hellmann, M. D. [1 ]
Rizvi, N. [1 ]
Gettinger, S. N. [2 ]
Goldman, J. [3 ]
Chow, L. Q. [4 ]
Juergens, R. [5 ]
Borghaei, H. [6 ]
Brahmer, J. [7 ]
Shen, Y. [8 ]
Harbison, C. T. [9 ]
Nathan, F. [10 ]
Ready, N. E. [11 ]
Antonia, S. J. [12 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, Div Solid Tumor Oncol, New York, NY 10021 USA
[2] Yale Comprehens Canc Ctr, Med Oncol, New Haven, CT USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Hematol Oncol, Los Angeles, CA 90024 USA
[4] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA
[5] Juravinski Canc Ctr, Dept Oncol, Hamilton, ON, Canada
[6] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA 19111 USA
[7] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Oncol, Baltimore, MD USA
[8] Bristol Myers Squibb Co, Biostat, Princeton, NJ USA
[9] Bristol Myers Squibb Co, Immunosci Metab Dis & Fibrosis, Princeton, NJ USA
[10] Bristol Myers Squibb Co, Clin Res, Princeton, NJ USA
[11] Duke Univ, Med Ctr, Div Oncol, Durham, NC USA
[12] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Dept, Tampa, FL 33612 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31738-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3097
引用
收藏
页码：S632 / S633
页数：2
相关论文
共 50 条
  • [21] First-Line Nivolumab plus Ipilimumab (NIVO plus IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227
    Borghaei, H.
    Brahmer, J. R.
    Lee, J. -S.
    Ciuleanu, T. -E.
    Caro, R. Bernabe
    Nishio, M.
    Urban, L.
    Audigier-Valette, C.
    Lupinacci, L.
    Sangha, R.
    Paz-Ares, L. G.
    Reck, M.
    O'Byrne, K. John
    Gupta, R. G.
    Bushong, J.
    Li, L.
    Blum, S. I.
    Eccles, L.
    Ramalingam, S. S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E8 - E9
  • [22] Survival of responders to nivolumab (NIVO) plus ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1
    Brahmer, J. R.
    Ciuleanu, T-E.
    Schenker, M.
    Audigier-Valette, C.
    Zurawski, B.
    Linardou, H.
    Kim, S-W.
    Otterson, G. A.
    Salman, P.
    De La Mora Jimenez, E.
    Lesniewski-Kmak, K.
    Ahmed, S.
    Albert, I.
    Barlesi, F.
    Feeney, K.
    Frickhofen, N.
    Li, A.
    Sun, P.
    Hellmann, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1444 - S1445
  • [23] First-line nivolumab (NIVO) plus ipilmumab (IPI) with two cycles of chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC): Results from an interim analysis of the non-interventional FINN study
    Kuon, J.
    von der Heyde, E.
    Bischoff, M.
    Wilop, S.
    Behringer, D.
    Blau, W.
    Huebner, G.
    Flieger, D.
    Forstbauer, H.
    Groschek, M.
    Laack, H.
    Mueller-Huesmann, H.
    Schumann, C.
    Waldenberger, D.
    Guetz, S.
    PNEUMOLOGIE, 2024, 78 : S102 - S103
  • [24] Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Han, B.
    Chu, T.
    Zhang, X.
    Zhong, H.
    Zhang, B.
    Wang, H.
    Gu, A.
    Zhang, W.
    Shi, C.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S398 - S398
  • [25] Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Shi, C.
    Zhong, H.
    Zhang, W.
    Zhang, B.
    Zhong, R.
    Zhang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S646 - S647
  • [26] NIVOLUMAB AND IPILIMUMAB IN FIRST-LINE NON-SMALL-CELL LUNG CARCINOMA (NSCLC): INTERIM PHASE I RESULTS
    Antonia, Scott J.
    Gettinger, Scott
    Chow, Laura Q.
    Juergens, Rosalyn
    Borghaei, Hossein
    Shen, Yun
    Harbison, Christopher
    Chen, Allen C.
    Ready, Neal E.
    Rizvi, Naiyer A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 155 - 155
  • [27] Nivolumab beyond First-Line (1L) Treatment in Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Sotelo, Miguel
    Chara, Luis
    Riquelme, Alejandro
    Toro, Piedad
    Lopez, Cynthia
    Hernando, Susana
    Caviedes, Edinson
    Aguayo, Cristina
    Bueno, Coralia
    Mielgo Rubio, Xabier
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1340 - S1341
  • [28] Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non-small cell lung cancer (NSCLC): Results from CheckMate 227.
    Brahmer, Julie R.
    Lee, Jong-Seok
    Ciuleanu, Tudor-Eliade
    Caro, Reyes Bernabe
    Nishio, Makoto
    Urban, Lazio
    Audigier-Valette, Clarisse
    Lupinacci, Lorena
    Sangha, Randeep S.
    Paz-Ares, Luis G.
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth John
    Gupta, Ravi
    Bushong, Judith
    Li, Li
    Blum, Steven I.
    Eccles, Laura
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [29] Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer
    Nishio, Makoto
    Kato, Terufumi
    Niho, Seiji
    Yamamoto, Noboru
    Takahashi, Toshiaki
    Nogami, Naoyuki
    Kaneda, Hiroyasu
    Fujita, Yuka
    Wilner, Keith
    Yoshida, Mizuki
    Isozaki, Mitsuhiro
    Wada, Shinsuke
    Tsuji, Fumito
    Nakagawa, Kazuhiko
    CANCER SCIENCE, 2020, 111 (05) : 1724 - 1738
  • [30] Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
    Merimsky, Ofer
    Cheng, Chi-Kin
    Au, Joseph Siu-Kie
    Von Pawel, Joachim
    Reck, Martin
    ONCOLOGY REPORTS, 2012, 28 (02) : 721 - 727
12345